For years, patients who wanted to avoid injectable biologics for psoriasis had limited oral options — and none of them performed remotely close to the injectable standard. In 2026, the oral landscape has expanded to three distinct medications: ICOTYDE (icotrokinra), Otezla (apremilast), and Sotyktu (deucravacitinib). They use different mechanisms, achieve different efficacy levels, carry different side effects, and cost different amounts. Pretending they are interchangeable would be a disservice.
Quick Answer: Ranking the Oral Psoriasis Treatments
ICOTYDE is the most effective oral psoriasis treatment available in 2026 (~70% PASI 90). Sotyktu occupies the middle tier (~40% PASI 90), and Otezla remains the weakest performer (~20% PASI 90) but the easiest to get covered by insurance. If efficacy is your primary concern and you can navigate insurance approval, ICOTYDE is the clear winner among oral options. If you need the fastest insurance approval with the fewest hurdles, Otezla remains the path of least resistance.
Three-Way Comparison Table
| Feature | ICOTYDE (Icotrokinra) | Sotyktu (Deucravacitinib) | Otezla (Apremilast) |
|---|---|---|---|
| Mechanism | IL-23 receptor peptide inhibitor | TYK2 inhibitor | PDE4 inhibitor |
| Approved | March 2026 | September 2022 | March 2014 |
| Dosing | Once daily | Once daily (6mg) | Twice daily (30mg) |
| PASI 90 | ~70% | ~40% | ~20% |
| PASI 75 | ~85% | ~58% | ~33% |
| PASI 100 | ~52% | ~18% | ~8% |
| Common Side Effects | Nausea (7%), diarrhea (6%) | Nasopharyngitis (12%), URI (8%), acne (6%) | Diarrhea (17%), nausea (15%), headache (12%) |
| Serious Safety Concerns | None in Phase 3 | Liver enzyme elevation; infection risk | Depression/suicidal ideation (rare); weight loss |
| Lab Monitoring | Baseline liver function | Periodic liver function tests | None required |
| Annual WAC Cost | ~$15,000–$20,000 | ~$36,000–$39,000 | ~$19,500–$21,000 |
| Insurance Ease | Medium (PA required; step therapy possible) | Difficult (high cost; strict PA) | Easy (well-established; widely covered) |
How Each Drug Works
ICOTYDE: Oral IL-23 Blockade
ICOTYDE targets the IL-23 pathway — the same pathway blocked by the most effective injectable biologics (Skyrizi, Tremfya). It is a constrained cyclic peptide that binds the IL-23 receptor, preventing IL-23 from activating Th17 cells and their downstream inflammatory cascade. This is the most targeted mechanism among oral options, which explains its superior efficacy.
Sotyktu: Selective TYK2 Inhibition
Sotyktu inhibits tyrosine kinase 2 (TYK2), an intracellular enzyme involved in signaling for multiple inflammatory cytokines including IL-23, IL-12, and type I interferons. This selective approach is more targeted than traditional JAK inhibitors, which explains why Sotyktu avoids the cardiovascular and thromboembolic risks associated with drugs like tofacitinib. Its efficacy sits between Otezla and ICOTYDE.
Otezla: PDE4 Inhibition
Otezla inhibits phosphodiesterase 4 (PDE4), an enzyme that regulates intracellular cAMP levels. By increasing cAMP, Otezla broadly damps down production of pro-inflammatory cytokines including TNF-alpha and IL-17 while increasing anti-inflammatory mediators. The mechanism is less targeted than either competitor, which explains both its lower efficacy and its higher rate of GI side effects.
Efficacy: Clear Hierarchy
There is a clear ranking among oral psoriasis treatments in 2026:
- ICOTYDE: ~70% PASI 90 — approaching injectable biologic territory
- Sotyktu: ~40% PASI 90 — meaningful improvement over Otezla but well below injectables
- Otezla: ~20% PASI 90 — adequate for mild-to-moderate disease but not competitive for severe psoriasis
For context, injectable IL-23 inhibitors achieve 80–90% PASI 90. ICOTYDE closes much of this gap from an oral formulation, while Otezla and Sotyktu remain substantially below injectable performance.
Side Effects: Different Profiles, Different Trade-offs
ICOTYDE: Mild and Transient GI Effects
Nausea (7%), diarrhea (6%), and headache (6%) are the most common. These are generally mild and resolve within the first few weeks. No serious safety signals emerged in Phase 3 trials.
Sotyktu: Respiratory and Skin Effects
Nasopharyngitis (12%), upper respiratory infections (8%), and acne (6%) are most common. Liver enzyme monitoring is required. The selective TYK2 mechanism avoids the serious cardiovascular risks of broader JAK inhibitors, but infection vigilance is still warranted.
Otezla: Significant GI Burden
Diarrhea (17%), nausea (15%), and headache (12%) affect a substantial proportion of patients, particularly during the first month. These side effects are the primary reason many patients discontinue Otezla. There is also a rare but important warning regarding depression and suicidal ideation.
If GI tolerance is your concern, ICOTYDE has the mildest profile despite being the most effective.
Cost and Insurance Reality
Cost comparisons reveal a surprising dynamic:
- ICOTYDE ($15–20K/year) is the least expensive of the three by list price, while being the most effective.
- Otezla ($19–21K/year) costs more than ICOTYDE despite significantly lower efficacy — but it has the easiest insurance pathway because insurers have covered it since 2014.
- Sotyktu ($36–39K/year) is by far the most expensive oral option with the most restrictive insurance requirements.
The insurance reality matters more than list price for most patients. Otezla is often the first oral drug covered without prior authorization. Many insurers require failure on Otezla before covering Sotyktu or ICOTYDE. This "step therapy" requirement can delay access to the more effective treatments by months.
Which Oral Psoriasis Treatment Is Right for You?
Choose ICOTYDE If:
- You want the strongest oral psoriasis treatment available
- You have moderate-to-severe disease and need high clearance
- You can navigate prior authorization (or have already tried Otezla/Sotyktu)
- You want a well-tolerated daily pill with minimal side effects
Choose Sotyktu If:
- ICOTYDE is not covered or available on your plan
- You have moderate disease where ~40% PASI 90 would be adequate
- You prefer a once-daily pill that is already established with your insurer
Choose Otezla If:
- You have mild-to-moderate psoriasis where ~20% PASI 90 is acceptable
- Insurance coverage is the deciding factor and you need the easiest approval
- You need a medication with no lab monitoring requirements
- You have a history that makes other oral options less suitable
Bottom Line
The oral psoriasis treatment landscape in 2026 has a clear best-in-class option: ICOTYDE. It is the most effective, well-tolerated, and (surprisingly) least expensive of the three. But insurance access, step therapy requirements, and individual medical history mean the "best" drug on paper is not always the "best" drug for your situation.
Use MedSwitcher to check your insurance coverage for all three oral psoriasis treatments and see estimated out-of-pocket costs. Then discuss the options with your dermatologist — and do not settle for a less effective treatment if you can advocate for the right one.